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Prolonged thrombocytopenia in a child with severe neonatal alloimmune
reaction and Noonan syndrome
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Abstract
Fetomaternal alloimmune thrombocytopenia (FMAIT) caused by maternal antibodies is the
leading cause of severe neonatal thrombocytopenia. A 1-month-old Caucasian girl was referred
to our Hematology Clinic for persistent thrombocytopenia diagnosed after a bleeding episode.
Diagnostic tests suggested FMAIT. Mild thrombocytopenia persisted for 18 months, and
subsequent findings of dysmorphic facies, short stature and mild pulmonary stenosis led to
the hypothesis of Noonan syndrome (NS), which was confirmed by genetic test. Other hema-
tological abnormalities were excluded and she had no further bleeding episodes. This case
illustrates the possibility of different diagnoses with the same clinical manifestations. The
persistence of thrombocytopenia longer than expected associated with typical physical fea-
tures led to the diagnosis of NS.
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Introduction
Fetomaternal alloimmune thrombocytopenia (FMAIT) is the lead-
ing cause of severe neonatal thrombocytopenia and may cause
intracranial hemorrhage (ICH) [1]. It is caused by transplacental
transfer of maternal antibodies (anti-HPA), after maternal sensi-
tization to paternally derived antigens, to fetal platelets, most
commonly HPA-1a (in 75–90% of cases). Less common antibo-
dies include anti-HPA-5b (10–15%) [1, 2]. When ICH is absent,
the prognosis is usually favorable and the platelet count typically
recovers to normal values within 8 to 10 days of life [1, 2]. For
reasons not well understood, a low count sometimes persists for
longer periods of time, occasionally for several months [3].
Case report
One month-old Caucasian girl, second child of a healthy A Rh+
mother, presented to our outpatient clinic with a history of per-
sistent thrombocytopenia.
The obstetric history was positive for mild maternal thrombo-
cytopenia during the third trimester (Platelets 119,000/µL). The
mother was immune to toxoplasmosis and cytomegalovirus, and
serologies were negative for other TORCH infections (including
syphilis and rubella). The child was born at 37 weeks of gestation,
with a birth weight of 3160 g and presented with umbilical cord
hemorrhage at birth and multiple ecchymoses. Her physical exam
was otherwise unremarkable. Blood tests revealed: hemoglobin
11.7 g/dL, reticulocyte count 8%, leukocytes 16,130/µL, platelets
14,000/µL, and normal prothrombin time and partial thrombo-
plastin time. During the first 2 weeks of life, platelet counts
continued to decrease (minimum of 6000/µL on the fourth day
of life) despite serial platelet transfusions (1st, 6th, 10th, 11th,
12th, and 13th days of life) and administration of IV immunoglo-
bulin 1 g/kg. Antiplatelet antibody HPA-3b was detected using
enzyme-linked immunosorbent assay (ELISA).
The genetic study of the patient showed a 1ab, 2aa, 3ab, 5ab,
4aa, 15ab genotype, while the mother’s genotype was 1ab, 2aa,
3aa, 5ab, 4aa, 15ab and the father’s genotype was 1ab, 2aa, 3ab,
5aa, 4aa, 15bb. In conclusion, the mother had HPA-3aa platelets,
the child HPA-3b platelets, and the cross-match showed that the
mother’s serum was strongly reactive against the father’s platelets.
The child was diagnosed with FMAIT. Cranial ultrasound was
negative for ICH and her echocardiogram showed only mild
pulmonary stenosis.
On the third week of life, her platelet count started to increase
to a maximum of 93,000/μL She required a red blood cell trans-
fusion due to anemia (hemoglobin: 9.1 g/dL) on the 25th day of
life and was discharged home as she was clinically stable.
The child was referred to our outpatient clinic when she was 1
month old, due to mild and persistent thrombocytopenia despite
the absence of episodes of hemorrhage or severe clinical mani-
festations. During follow-up in the first year of life (with platelet
counts 48,000–110,000/µL), a dysmorphic facies (high forehead,
low set ears, and micrognathia), failure to thrive, and short stature
became increasingly apparent, leading to the hypothesis of
Noonan syndrome (NS). A mutation in the PTPN11 gene
c.181G>A in exon 3 was identified. Further tests for NS—renal
ultrasound, thyroid function, coagulation factor assays (V, VII,
VIII, IX, X, XI, XII, XIII, von Willebrand), and platelet aggrega-
tion as evaluated with PFA 100—revealed no other abnormalities.
She is now 19 months old and has had no further evidence of
mucocutaneous bleeding.
Conclusion
NS is a relatively common congenital genetic disorder with an
estimated prevalence of 1 in 1000 to 1 in 2500 live births [4].
Characteristic findings include distinctive facial features, short
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stature, chest deformity, and congenital heart disease, which may
not be apparent during the first months of life and require a high
index of suspicion during follow-up [5, 6]. It is an autosomal
dominant disorder with complete penetrance but variable expres-
sivity [3]. Mutations in PTPN11 occur in 50% of patients, SOS1
in 13%, RAF in 3–17%, and KRAS in less than 5% [7].
PTPN11 encodes SH2 domain, which contains protein-tyro-
sine phosphatases Shp1 and Shp2; Shp1 is expressed in hemato-
poietic and epithelial cells, while Shp2 is expressed widely and
they are both key regulators in megakaryocyte development,
platelet formation, and function (including interaction with col-
lagen and fibrinogen); these two phosphatases seem to have
opposite roles in platelet function (Shp1 reduces platelet response
to collagen and fibrinogen by positively regulating immune recep-
tor tyrosine-based activation motif-containing receptors and
integrin signaling, whilst Shp2 behaves in the opposite way) [8].
Several hematological abnormalities have been detected in
association with this syndrome including thrombocytopenia that
may be severe; cases that resemble congenital amegakaryocytic
thrombocytopenia have been described and may be caused by
specific PTPN11 mutations (c.218C>T) [9, 10]. Although the
mechanism responsible for this phenomenon is still incompletely
understood, ineffective thrombopoiesis and spleen sequestration
are two of the main hypotheses 11, 12]. Other hematological
disorders include abnormal platelet function and deficiency of
single or multiple coagulation factors (most commonly partial
deficiency of factor XI) [4–7, 11–13].
Persistence of thrombocytopenia beyond the second week of life
in a child diagnosed with FMAIT should prompt further investiga-
tion to exclude other etiologies. In this case, persistence of throm-
bocytopenia longer than expected associated with dysmorphic
facies, pulmonic valve stenosis, developmental delay, and short
stature led to the diagnosis of NS. The clinical presentation of
severe thrombocytopenia at birth was probably due to the associa-
tion between the immunemechanism and the congenital cause [14].
This case illustrates the fact that different diagnoses with the
same clinical manifestations should be taken into consideration
when expected evolution does not occur.
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